<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111981</url>
  </required_header>
  <id_info>
    <org_study_id>VDC2009O</org_study_id>
    <nct_id>NCT01111981</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia</brief_title>
  <official_title>Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Callender Center for Clinical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Callender Center for Clinical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to ascertain the safety and efficacy of

      Clobetasol Propionate 0.05% E Foam in the treatment of Central Centrifugal

      Cicatricial Alopecia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central Centrifugal Cicatricial Alopecia (CCCA) is an inflammation-induced

      hair loss starting in the central scalp and progressing centrifugally. The

      cause of CCCA is unknown. Early diagnosis and treatment is essential to stop

      or slow the progression of scarring and permanent hair loss. Once scarring

      occurs, the hair follicles are obliterated and the hair cannot regrow. Thus,

      anti-inflammatory medications are used to decrease inflammation. Current

      treatment includes topical and intralesional corticosteroids, oral

      antibiotics, and hair transplantation, all which may take months to years to

      show improvement. There is no evidence-based medicine on how to treat

      primary cicatricial alopecias. Clobestasol Propionate 0.05% Emollient Foam is

      an FDA-approved and marketed topical corticosteroid for the treatment of the

      inflammatory and pruritic manifestations of moderate to severe corticosteroid-

      responsive dermatoses of the scalp. Many studies found the foam to be less

      irritating than the original formulation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">October 2010</completion_date>
  <primary_completion_date type="Anticipated">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of pruritis, tenderness, and pain</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of inflammation on biopsy</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Alopecia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobetasol Propionate 0.05% Emollient Foam</intervention_name>
    <description>Clobetasol Propionate 0.05% E Foam to be applied to affected area once a day for 16 weeks</description>
    <other_name>Olux-E</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CCCA, treated or untreated

          -  Score 0 - 1 on Scale/Questionnaire

          -  18 years of age or older

          -  Women of African descent

        Exclusion Criteria:

          -  Score &gt; 1 on Scale/Questionnaire

          -  Alopecias other than CCCA, including alopecia arreata, lichen planopilaris,
             trichotillomania, and traction alopecia

          -  History of hair transplantation

          -  Children less than 18 years of age

          -  Males

          -  Women of non-African descent

          -  Pregnancy or breastfeeding. Women of childbearing age must use reliable forms of
             contraception (e.g., abstinence, oral contraceptives, or spermicide and condoms)

          -  Anti-dandruff shampoo within 30 days

          -  Anti-inflammatory medications such as antibiotics (doxycycline, minocycline, rifampin,
             etc.), steroids (oral prednisone, topical corticosteroids,etc.), NSAIDs (ibuprofen,
             aspirin, etc.)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valerie Callender, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Callender Skin for Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cherie Young, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Callender Center for Clinical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynn Carter, BA</last_name>
    <phone>301-249-0970</phone>
    <email>clinresearch@callenderskin.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cherie Young, M.D.</last_name>
    <phone>301-249-0970</phone>
    <email>clinresearch@callenderskin.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Callender Center for Clinical Research</name>
      <address>
        <city>Mitchellville</city>
        <state>Maryland</state>
        <zip>20721</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Carter, BA</last_name>
      <phone>301-249-0970</phone>
      <email>clinresearch@callenderskin.com</email>
    </contact>
    <contact_backup>
      <last_name>Niccole Mathews</last_name>
      <phone>301-249-0970</phone>
      <email>clinresearch@callenderskin.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.callenderskin.com</url>
    <description>Home Page to the Callender Skin &amp; Laser Center that includes &quot;Research Studies&quot; section</description>
  </link>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2010</study_first_submitted>
  <study_first_submitted_qc>April 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2010</study_first_posted>
  <last_update_submitted>April 27, 2010</last_update_submitted>
  <last_update_submitted_qc>April 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Valerie Callender, M.D.</name_title>
    <organization>Callender Center for Clinical Research</organization>
  </responsible_party>
  <keyword>alopecia</keyword>
  <keyword>CCCA - Central Centrifugal Cicatricial Alopecia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
    <mesh_term>Emollients</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

